A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 10,400 shares of ENTA stock, worth $117,520. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,400
Previous 9,400 10.64%
Holding current value
$117,520
Previous $164,000 18.29%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.43 - $17.02 $4.68 Million - $6.98 Million
409,812 Added 737.56%
465,375 $6.04 Million
Q1 2024

May 15, 2024

SELL
$10.08 - $17.46 $109,700 - $190,017
-10,883 Reduced 16.38%
55,563 $970,000
Q4 2023

Feb 14, 2024

SELL
$8.18 - $10.78 $1.06 Million - $1.4 Million
-129,795 Reduced 66.14%
66,446 $625,000
Q3 2023

Nov 14, 2023

SELL
$11.09 - $22.13 $177,184 - $353,571
-15,977 Reduced 7.53%
196,241 $2.19 Million
Q2 2023

Aug 14, 2023

SELL
$20.68 - $39.85 $1.63 Million - $3.14 Million
-78,739 Reduced 27.06%
212,218 $4.54 Million
Q1 2023

May 15, 2023

BUY
$38.82 - $54.59 $7.02 Million - $9.87 Million
180,891 Added 164.35%
290,957 $11.8 Million
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $3.1 Million - $4.09 Million
76,104 Added 224.09%
110,066 $5.12 Million
Q3 2022

Nov 14, 2022

BUY
$48.29 - $71.27 $1.64 Million - $2.42 Million
33,962 New
33,962 $1.76 Million
Q1 2022

May 16, 2022

BUY
$56.06 - $74.11 $379,582 - $501,798
6,771 Added 29.18%
29,972 $2.13 Million
Q4 2021

Feb 14, 2022

SELL
$60.19 - $97.37 $1.58 Million - $2.56 Million
-26,293 Reduced 53.12%
23,201 $1.73 Million
Q3 2021

Nov 15, 2021

SELL
$41.02 - $58.65 $1.65 Million - $2.36 Million
-40,253 Reduced 44.85%
49,494 $2.81 Million
Q2 2021

Aug 16, 2021

SELL
$43.76 - $53.11 $393,489 - $477,565
-8,992 Reduced 9.11%
89,747 $3.95 Million
Q1 2021

May 17, 2021

BUY
$41.69 - $54.95 $450,668 - $594,009
10,810 Added 12.29%
98,739 $4.87 Million
Q4 2020

Feb 16, 2021

BUY
$41.16 - $47.47 $1.45 Million - $1.67 Million
35,140 Added 66.57%
87,929 $3.7 Million
Q3 2020

Nov 16, 2020

BUY
$43.36 - $53.53 $429,437 - $530,161
9,904 Added 23.09%
52,789 $2.42 Million
Q2 2020

Aug 14, 2020

SELL
$46.37 - $57.58 $4.16 Million - $5.16 Million
-89,608 Reduced 67.63%
42,885 $2.15 Million
Q1 2020

May 15, 2020

BUY
$40.22 - $62.0 $3 Million - $4.62 Million
74,579 Added 128.78%
132,493 $6.81 Million
Q4 2019

Feb 14, 2020

SELL
$57.95 - $66.61 $1.9 Million - $2.18 Million
-32,749 Reduced 36.12%
57,914 $3.58 Million
Q3 2019

Nov 14, 2019

SELL
$60.08 - $88.17 $10.5 Million - $15.5 Million
-175,444 Reduced 65.93%
90,663 $5.45 Million
Q2 2019

Aug 14, 2019

BUY
$81.3 - $97.35 $1.33 Million - $1.59 Million
16,335 Added 6.54%
266,107 $22.5 Million
Q1 2019

May 15, 2019

BUY
$69.08 - $105.66 $16.5 Million - $25.3 Million
239,141 Added 2249.47%
249,772 $0
Q4 2018

Feb 14, 2019

BUY
$65.41 - $84.65 $177,522 - $229,740
2,714 Added 34.28%
10,631 $752,000
Q3 2018

Nov 13, 2018

SELL
$85.46 - $126.37 $963,305 - $1.42 Million
-11,272 Reduced 58.74%
7,917 $0
Q2 2018

Aug 10, 2018

BUY
$81.85 - $120.51 $97,810 - $144,009
1,195 Added 6.64%
19,189 $0
Q1 2018

May 11, 2018

BUY
$57.91 - $92.15 $676,620 - $1.08 Million
11,684 Added 185.17%
17,994 $1.46 Million
Q3 2017

Nov 09, 2017

BUY
$37.91 - $46.8 $239,212 - $295,308
6,310
6,310 $295,000

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $234M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.